DeutschNewstral
Article
bizjournals.com on 2020-01-10 20:20
Cambridge startup raises $110M for re-doseable gene therapies
Related news
- Another Cambridge gene-editing startup raises millions in fundingbizjournals.com
- Study raises concerns over gene-editing, hitting Cambridge biotechs hardbizjournals.com
- Cambridge ‘voice skins’ startup Modulate raises $2M in seed fundingbizjournals.com
- Exclusive: Gene editing pioneer Feng Zhang launches new startup in Cambridgebizjournals.com
- Virtual gene editing startup to lease Cambridge lab after $40M roundbizjournals.com
- Form D Friday: Cambridge gene editing company raises this week's largest roundbizjournals.com
- Vertex-partnered gene therapy startup raises $110Mbizjournals.com
- Cambridge startup raises $16.5M to help humans and robots work togetherbizjournals.com
- Cambridge RNA startup raises $45M to break into CNS, liver diseasebizjournals.com
- Cambridge startup Weathermob acquiredbizjournals.com
- Biotech startup Alector raises $29.5M for Alzheimer's disease therapiesbizjournals.com
- Chapel Hill gene therapy startup raises $50Mbizjournals.com
- Indian biopharma spins out Cambridge oncology startupbizjournals.com
- Cambridge cancer startup Oncorus expands to Andoverbizjournals.com
- Cambridge database tech startup lands $9.5Mbizjournals.com
- FBI investigates Cambridge microbiome startup, report saysbizjournals.com
- Biotech startup expands from Cambridge to Watertownbizjournals.com
- Dassault Systèmes to acquire Cambridge database startupbizjournals.com
- Cambridge gene-editing firm eyes IPO, discloses Novartis dealbizjournals.com
- Rockville biotech buys Cambridge gene therapy firm for $86Mbizjournals.com